Topical treatment of recurrent herpes simplex with cytosine arabinoside.
A double-blind controlled clinical trial of the topical use of cytosine arabinoside in recurrent herpes simplex of the face and genital region showed no significant difference in the efficiency of a placebo as compared with cytosine arabinoside. The high rate of placebo response (70%) found in this trial makes the assessment of any drug treatment for herpes simplex particularly difficult.
D000287:Administration, Topical; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000188:drug therapy; D005835:Genitalia; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D010865:Pilot Projects; D010919:Placebos; D012008:Recurrence
D010919:Placebos; D003561:Cytarabine